Overall Score

Revenue Model

BCYC remains a non-dividend biotech with revenue concentrated in product/partnering activity rather than recurring subscription-like cash flows.

Price-to-sales is 4.42x, indicating the market still assigns meaningful value to the revenue base despite negative earnings and cash flow.

Profitability

Margins remain deeply negative, with operating margin at -3.44 and net margin at -3.11, showing the business is still loss-making.

Return on equity (-0.33) and return on invested capital (-0.38) remain weak, reflecting limited current profitability.

Balance Sheet

Liquidity is very strong, with a current ratio of 12.08 and cash ratio of 10.71, giving the company substantial near-term flexibility.

Debt remains modest relative to capital, with debt-to-equity at 0.03 and debt-to-assets at 0.02, reducing balance-sheet stress.

Cash Generation

Operating cash flow and free cash flow remain negative, with free cash flow per share at -2.95 and operating cash flow per share at -2.95.

Despite negative cash generation, the company’s cash position and low leverage help cushion ongoing burn.

Growth Scalability

Asset turnover is only 0.10, suggesting limited current efficiency in converting assets into revenue.

R&D intensity remains high at 3.27x revenue, which supports pipeline investment but also keeps the model capital-intensive.